Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

ABSTRACT:

Aims

Neuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin-releasing peptide (GRP), derived from the precursor proGRP1-125 (proGRP), has recently been implicated in inflammation and wound repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction.

Methods and results

The association between plasma proGRP (time-resolved immunofluorometric assay) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anaemia, enrolled in the Reduction of Events by Darbepoetin alfa in Heart Failure (RED-HF) trial. Median proG

SUBMITTER: Ueland T 

PROVIDER: S-EPMC6300802 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature